Last reviewed · How we verify
Loading bolus of cefoxitin
Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefoxitin is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical site infection prophylaxis, Mixed aerobic-anaerobic infections, Intra-abdominal infections.
At a glance
| Generic name | Loading bolus of cefoxitin |
|---|---|
| Sponsor | Poitiers University Hospital |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Cefoxitin works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, including anaerobes, making it useful for surgical prophylaxis and mixed infections. A loading bolus provides rapid achievement of therapeutic concentrations.
Approved indications
- Surgical site infection prophylaxis
- Mixed aerobic-anaerobic infections
- Intra-abdominal infections
Common side effects
- Hypersensitivity reactions (rash, urticaria)
- Diarrhea
- Phlebitis at injection site
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loading bolus of cefoxitin CI brief — competitive landscape report
- Loading bolus of cefoxitin updates RSS · CI watch RSS
- Poitiers University Hospital portfolio CI